Neoadjuvant therapy for resectable pancreatic cancer: An evolving paradigm shift

Akhil Chawla, Cristina R. Ferrone*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


Non-metastatic pancreatic adenocarcinoma (PDAC) is associated with a high rate of recurrence and lethality. In addition, less than half of all patients are able to complete systemic therapy after curative-intent pancreatectomy. With its well-known potential benefits, this report highlights the current prospective data relevant to the use of neoadjuvant systemic therapy in resectable PDAC. Recently, there have been numerous reports, many of which consist of long-awaited multi-intuitional trial data evaluating the use of neoadjuvant systemic chemotherapy in non-metastatic PDAC as well as the use of combination chemotherapy regimens in the adjuvant setting. Currently, recommended guidelines for neoadjuvant systemic therapy only exist for borderline-resectable and locally-advanced disease. Given the plethora of new data, there has been a shift in the paradigm of how resectable pancreatic cancer is treated at certain centers across the world. This review highlights the relevant available data from recent sentinel prospective trials and how they relate to the systemic treatment of resectable PDAC in the neoadjuvant setting.

Original languageEnglish (US)
Article number1085
JournalFrontiers in Oncology
Issue numberOCT
StatePublished - 2019
Externally publishedYes


  • Adjuvant
  • Chemotherapy
  • Neoadjuvant
  • Pancreatic adenocarcinoma
  • Resectable

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Neoadjuvant therapy for resectable pancreatic cancer: An evolving paradigm shift'. Together they form a unique fingerprint.

Cite this